Pharmafile
Is the Current EU Legal Framework for Orphan Medicines Fit for Purpose?
Autumn 2019
Maria Isabel Manley, partner and head of the UK Global Life Sciences Practice, and Chris Boyle, associate, at Sidley, discuss the impact of regulatory frameworks on medicines for rare diseases.
Contacts
Capabilities
Suggested News & Insights
OIG Signals Further Support for Manufacturer-Sponsored Testing Programs with Fourth Favorable Advisory OpinionJuly 8, 2026Sidley Represents Abbisko Therapeutics in Its US$1.9 Billion Strategic Collaboration With Eli Lilly and Co.July 2, 2026Sidley Represents Caidya in Strategic Combination with Simbec-OrionJune 30, 2026Sidley Represents Bio-Techne in Its US$11.3 Billion Acquisition by Merck KGaAJune 25, 2026Don't Touch That Thermostat: Senate Examines Consumer Product Safety Commission Nominees Amid Agency OverhaulsJune 24, 2026The EU AI Act’s Machinery Exemption: Does It Extend to Surgical Robotics?June 11, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory